"Bisphosphonate drugs for osteoporosis do not seem to increase the risk of femoral fractures, the FDA announced Wednesday, though the agency will continue to evaluate that possibility.
Even as the FDA was making its announcement in Washington, orthopedic surgeons gathered in New Orleans were
hearing news of a study showing an eventual decline in bone quality among patients who took bisphosphonates for more than four years.
The FDA issued its statement as a result of case reports suggesting that "atypical" subtrochanteric femur fractures were occurring at higher-than-expected rates in women taking bisphosphonate drugs for osteoporosis....."
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.